What is Lifesci Capital’s Forecast for TARS Q1 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Analysts at Lifesci Capital lowered their Q1 2026 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued on Wednesday, May 6th. Lifesci Capital analyst F. Brisebois now expects that the company will post earnings per share of ($0.64) for the quarter, down from their previous estimate of ($0.52). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($0.74) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.27) EPS and FY2026 earnings at ($0.98) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.32%. The firm had revenue of $162.05 million during the quarter, compared to analyst estimates of $149.60 million.

TARS has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, April 21st. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Zacks Research lowered shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Guggenheim lifted their price objective on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Friday, April 24th. They set an “outperform” rating and a $98.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $90.67.

Tarsus Pharmaceuticals Stock Down 1.2%

Tarsus Pharmaceuticals stock opened at $63.96 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85. Tarsus Pharmaceuticals has a 52-week low of $38.51 and a 52-week high of $85.25. The firm has a 50 day moving average price of $68.72 and a two-hundred day moving average price of $71.87. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of -56.11 and a beta of 0.52.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC increased its stake in Tarsus Pharmaceuticals by 139.2% during the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after purchasing an additional 291 shares in the last quarter. Swiss National Bank increased its stake in Tarsus Pharmaceuticals by 0.8% during the 1st quarter. Swiss National Bank now owns 62,933 shares of the company’s stock valued at $4,415,000 after purchasing an additional 500 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Tarsus Pharmaceuticals by 0.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 131,612 shares of the company’s stock valued at $9,242,000 after purchasing an additional 1,232 shares in the last quarter. Calamos Advisors LLC increased its stake in Tarsus Pharmaceuticals by 27.3% during the 1st quarter. Calamos Advisors LLC now owns 43,832 shares of the company’s stock valued at $3,075,000 after purchasing an additional 9,390 shares in the last quarter. Finally, Principal Financial Group Inc. bought a new stake in Tarsus Pharmaceuticals during the 1st quarter valued at $200,000. Institutional investors own 90.01% of the company’s stock.

Insider Activity at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 11,964 shares of the business’s stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $801,588.00. Following the transaction, the chief executive officer owned 33,421 shares in the company, valued at $2,239,207. The trade was a 26.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William J. Phd Link sold 12,500 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $68.79, for a total transaction of $859,875.00. Following the transaction, the director owned 116,332 shares in the company, valued at $8,002,478.28. The trade was a 9.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 79,391 shares of company stock worth $5,432,035 over the last quarter. 8.97% of the stock is currently owned by insiders.

Key Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Q1 beat on both EPS and revenue; company reported ($0.16) EPS vs. consensus ($0.40) and revenue of $162.05M vs. ~$149.6M expectation — driven by XDEMVY net product sales > $145M (up >85% YoY). Management reaffirmed full?year XDEMVY guidance of $670–700M and reiterated multi?year peak sales potential >$2B, supporting the commercial story. Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
• Positive Sentiment: Commercial traction: management said nearly half of core eye care professionals prescribe XDEMVY weekly and DTC and evidence programs are driving deeper utilization — supports revenue durability and upside to analyst sales models. Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
• Positive Sentiment: Pipeline expansion: Tarsus initiated the Calliope Phase 2 trial of TP?05 (oral Lyme disease prevention), adding a non?ophthalmic growth optionality with topline expected in H1 2027. This is longer?dated upside for investors. Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
• Neutral Sentiment: Investor materials and access: company posted the earnings presentation and hosted the conference call; management will also attend investor conferences — increases transparency and provides opportunities for guidance color. Tarsus Pharmaceuticals, Inc. 2026 Q1 – Results – Earnings Call Presentation Tarsus to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Earnings call transcript and summaries are available for detail on margin drivers and marketing spend — useful for modeling near?term profitability and cash flow. Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript Tarsus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
• Negative Sentiment: Analyst estimate revisions are mixed: HC Wainwright updated several quarterly estimates (some higher for later quarters but trimmed FY2026 slightly) and keeps a Buy/$88 target — still bullish but shows modeling uncertainty. Lifesci Capital lowered its Q4 2026 EPS estimate (from $0.09 to $0.05) despite maintaining a Strong?Buy — signals divergent near?term EPS views that may pressure shares. (Sources: analyst notes summarized by market outlets.)

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro?effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early?stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.